SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Up 122.2% in March

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 2,000 shares, an increase of 122.2% from the February 28th total of 900 shares. Based on an average daily volume of 29,200 shares, the short-interest ratio is presently 0.1 days.

SAB Biotherapeutics Price Performance

Shares of NASDAQ SABSW traded down $0.00 during mid-day trading on Friday, hitting $0.03. The company had a trading volume of 3,075 shares, compared to its average volume of 22,991. SAB Biotherapeutics has a one year low of $0.01 and a one year high of $0.18. The firm has a 50-day simple moving average of $0.04 and a two-hundred day simple moving average of $0.05.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.